Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis. According to Globaldata, it is involved in 6 clinical trials, of which 2 were completed, 1 is ongoing, 2 are planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Cannabidiol 1’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Cannabidiol 1 is expected to reach an annual total of $210 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Cannabidiol 1 Overview
Cannabidiol is under development for the treatment of myocardial fibrosis, acute myocarditis, non-ischemic cardiomyopathy and recurrent pericarditis. It acts by targeting cannabinoid receptors (CB1 and CB2). It is developed based on the proprietary nanotechnology platform. It is administered through oral route and subcutaneous.
The drug candidate was under development for the treatment of hospitalized COVID-19 patients with a prior history of or risk factors for cardiovascular disease (CVD) and diastolic heart failure.
Cardiol Therapeutics Overview
Cardiol Therapeutics (Cardiol) is a clinical-stage life sciences company. It researches and develops anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate CardiolRx is used to treat inflammatory heart diseases. It is also evaluating therapies against acute myocarditis and heart failure. Cardiol is developing its proprietary nanotherapeutics technology to deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to sites of inflammation in the heart. Cardiol is headquartered in Oakville, Ontario, Canada.
The operating loss of the company was CAD29.8 million in FY2023, compared to an operating loss of CAD41.3 million in FY2022. The net loss of the company was CAD28.1 million in FY2023, compared to a net loss of CAD30.9 million in FY2022.
For a complete picture of Cannabidiol 1’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
